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Three-dimensional quantitative structure-activity relationship (3D-QSAR) studies were performed on a series of 
substituted 1,4-dihydroindeno[1,2-c]pyrazoles inhibitors, based on molecular docking scores obtained by using 
GOLD 3.01, with comparative molecular field analysis (CoMFA). The docking results provided a reliable 
conformational alignment scheme for the 3D-QSAR model. Based on the docking conformations and alignments, 
highly predictive CoMFA model was obtained with cross-validated q2 value of 0.534 and non-cross-validated 
partial least-squares (PLS) analysis with the optimum components of six showed a conventional r2 of 0.911. The 
predictive ability of this model was validated by the testing set with a conventional r2 value of 0.812. The 
information obtained from the CoMFA 3D contour maps enables the interpretation of their structure-activity 
relationship and was also used to the design of several new inhibitors with improved activity. 
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1. Introduction 
DNA-damaging anticancer agents is the mainstay of cancer treatment and has produced significant 
increases in the survival of cancer patients when used in combination with drugs that have different 
mechanisms of actions[1] .However, the clinical use of DNA-damaging anticancer agents is limited by 
their severe toxicity and by resistance from tumor cells. So, it is important to develop highly 
efficacious and minimally toxic treatments for cancer. Recently, the development of adjuvant 
therapeutics has been aggressively pursued. Such treatments may either sensitize tumor tissue or 
protect normal tissue from DNA damage [2]. 
With DNA damage, cells are arrested (G1, S, G2) to initiate the DNA repair process [3-5]. Most 
tumor cells distinguish themselves from normal cells by lacking the G1 checkpoint due to loss of p53, 
and therefore they are selectively arrested at the S or G2 checkpoint after DNA damage. If the S and 
G2 checkpoints are abrogated, G1-deficient cancer cells will lead cell death. In contrast, normal cells 
are still arrested in the G1 phase and are less affected by S and G2 checkpoint abrogation, suggesting 
that a favorable therapeutic window may be achieved for G2 and/or S abrogators [6]. 
Checkpoint kinase 1 (CHK1) is a serine/threonine protein kinase and a key mediator in the DNA 
damage-induced checkpoint network, and it is activated via activation of the upstream ATM/ATR 
pathway[ 7-10].Activation of CHK1 results in phosphorylation of Cdc25A at Ser123 and several other 
serine residues and Cdc25C at Ser216. The downstream event is the inhibition of cyclin E/Cdk2 or  
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cyclin B/Cdc2 kinases, which ultimately causes cell cycle arrest at S or G2 phase [11] .The inhibitors 
of CHK1 abrogate the S and G2 checkpoints, thereby preferentially sensitizing tumor cells, especially 
p53-null cells. Consequently, CHK1 has emerged as an attractive chemosensitization target, and the 
inhibitors of CHK1 may significantly improve the efficacy and selectivity of DNA-damaging agents in 
the clinic [6] .  
In recent years, a number of CHK1 inhibitors have appeared in the primary literatures. Among 
them, Yunsong Tong et al. found that compound 1 (Figure 1 ) was a potent inhibitor of CHK1 (IC50  
510 nM). Moreover, they synthesized a series of 1,4-dihydroindeno[1,2-c]pyrazoles derivatives as 
potent, selective CHK1 inhibitors. The binding modes of this series of CHK1 inhibitors have been 
determined by X-ray crystallography, which provided not only insights into the interaction mechanisms 
of CHK1 with the inhibitors, but also valuable clues for designing new inhibitors. In this paper, with 
the molecular docking and Three-Dimensional(3-D) QSAR (CoMFA) analyses. It is possible to get 
new insights into the relationship between the structural information of a series of substituted 
1,4-dihydroindeno[1,2-c]pyrazoles inhibitors and the inhibitory potency, aimed at identifying structural 
features in CHK1 that can be used to design new inhibitors. 
 
2. COMPUTATIONAL DETAILS 
2.1 Biological Data and Molecular Structures 
We gathered a panel of 151 structurally and pharmacologically diverse compounds for the 3D QSAR 
analysis from four publications reported by one laboratory [2，11，14-15].Because of the similar 
experimental procedures applied for affinity determination in each publication, the biological data 
(represented as IC50 values) were considered comparable and thus merged into our study. The IC50 
values, in nM, were converted to pIC50 (-log IC50) values, which were used as dependent variables in 
the QSAR analyses. The biological data were divided into a training set and a testing set as shown in 
Table 1, 2 and 3. The training set which was selected randomly consists of 121 compounds and the 
testing set is comprised of 30 compounds. 
The 3D structures of these compounds were carried out on a personal computer with the RHEL 
4.0 operating system using SYBYL 8.0. The 3D structures of the training and test set of compounds 
were constructed using the Sketch Molecule function in SYBYL. Partial atomic charges were 
calculated by the Gasteiger-Hückel method and energy minimizations were performed using the Tripos 
force field with a distance-dependent dielectric and the Powell conjugate gradient algorithm 
(convergence criterion of 0.005 kcal/mol/Å). 
2.2 Docking Studies 
For the docking of ligands to protein active sites and for estimating the binding affinities of docked 
compounds, an advanced molecular docking program GOLD version 3.01 , with a powerful genetic 
algorithm (GA) method for conformational search and docking programs, was used in this study. 

































































Atomic coordinates for the CHK1 complex with CHK2759M41, used for our modeling, have been 
deposited in the Brookhaven Protein Data Bank (PDB ID: 2E9N).The original ligand was removed 
from the coordinated set. The genetic operators were 100 for the population size, 1.1 for the selection, 5 
for the number of subpopulations, 100000 for the maximum number of genetic applications, and 2 for 
the size of the niche used to increase population diversity. The weights were chosen so that crossover 
mutations were applied with equal probability (95/95 for the values), and migration was applied 5% of 
the time. ChemScoring function encoded in GOLD was applied to predict binding positions between 
CHK1 and 150 inhibitors. The fitness score is taken as the negative of the sum of the component 
energy terms, so that larger fitness scores are better [12]. 
 
2.3. Structural alignment 
Molecular alignment is the most sensitive parameter in 3D-QSAR analysis. This renders the spatial 
alignment of molecules under study as one of the most sensitive and determining factors in obtaining 
robust and meaningful models. Ten conformations were obtained using GOLD for each ligand, in 
which the training set contained the conformations with the top-ranked ChemScores while the test set 
contained the conformations with the lowest residues between actual and predicted pIC50 predicted by 
the CoMFA model of the training set. 121 inhibitors were selected randomly as the training set, and 
these inhibitors were aligned together for CoMFA study to explore the specific contributions of 
electrostatic and steric effects of the molecular bioactivities. 
 
2.4 CoMFA 
Steric and electrostatic interactions were calculated using the Tripos force field with a 
distance-dependent dielectric constant at all intersections in a regular space (2 Å) grid taking a sp3 
carbon atom as steric probe and all charge as electrostatic probe. The cutoff was set to 30 kcal/mol. 
With standard options for scaling of variables, the regression analysis was carried out using the full 
cross-validated partial least-squares (PLS) method of LOO (leave-one-out). The minimum-sigma 
(column filtering) was set to 2.0 kcal/mol to improve the signal-to-noise ratio by omitting those lattice 
points whose energy variation was below this threshold. The final model, a non-cross-validated 
conventional analysis, was developed with the optimum number of components to yield a 
non-cross-validated r2 value [13]. 
3 Results and Discussion 
3.1. Docking study 
In order to determine the probable binding conformations of these substituted 
1,4-dihydroindeno[1,2-c]pyrazoles , GOLD was used to dock all compounds into the active sites of 
CHK1. The docking reliability was validated using the known X-ray structure of CHK1 in complex 
with a small molecular ligand CHK2759M41. The ligand CHK2759M41 was redocked to the binding 

































































sites of CHK1 and the docked conformation corresponding to the lowest free energies was selected as 
the most probable binding conformation. The root-mean-square deviation (RMSD) between the 
conformations of cocrystallized CHK2759M41 and redocked CHK2759M41 was equal to 1.118 Å, 
suggesting that a high docking reliability of GOLD in reproducing the experimentally observed binding 
mode for CHK1 inhibitors and the parameters set for the GOLD simulation was reasonable to 
reproduce the X-ray structure. Just as shown in Figure 2, the cocrystallized CHK2759M41 and 
redocked CHK2759M41 are almost at the same position in the active sites of CHK1. Therefore, the 
GOLD method and the parameters set could be extended to search the CHK1 binding conformations 
for other inhibitors. 
The predicted binding free energies (ChemScore) for all the inhibitors are listed in Table 2 and 3, 
and the pIC50 of the inhibitors are shown in Tables 1. Figure 3 represents the interaction model of the 
docked inhibitor CHK2759M41 with CHK1. Inhibitor CHK2759M41 binds to the active site and 
makes several interactions with the hinge-binding region of the enzyme. 
As show in figure 3, inhibitor CHK2759M41 forms six hydrogen bonds with Glu55, Phe149, 
Asn59, Cys87, Glu85 and Leu15. The phenyl ring interacts with the hydrophobic surface of the side 
chains of Leu84, Ile56, Val56 and Phe149. Also, the cyclohexane ring interacts with the hydrophobic 
surface of the side chains of Tyr86, Ser88, Thr14, Asp94 and Glu17. Figure 4 illustrates the probable 
binding conformational alignment for the the 151 substituted 1, 4-dihydroindeno[1,2-c]pyrazoles 
inhibitors chosen from the docked conformations. 
 
3.2  CoMFA model 
The CoMFA analysis was performed to explore the structure-activity relationship of substituted 
1,4-dihydroindeno[1,2-c]pyrazoles inhibitors of CHK1. PLS analysis was carried out for the 121 
training set, and the result is listed in Table 4, which showed that a CoMFA model with a 
cross-validated q2 of 0.534 for 6 components was obtained. The non-cross-validated PLS analysis with 
the optimum components of 6 revealed a conventional r2 value of 0.911, F =187.106, and an estimated 
standard error of 0.352. The steric field descriptors explain 43.0% of the variance, while the 
electrostatic descriptors explain 57.0%. The predicted activities for the 151 inhibitors versus their 
experimental activities with their residues are listed in Tables 2 and 3, and the correlation between the 
predicted activities and the experimental activities are depicted in Figure 5 and 6. Those values indicate 
a good statistical correlation and reasonable predictability of the CoMFA model. 
The steric interaction is represented by green and yellow contours, in which green-colored regions 
indicate areas where increased steric bulk is associated with enhanced activity, and yellow regions 
suggest areas where increased steric bulk is unfavourable. Electrostatic interaction is indicated by red 
and blue contours, among which blue-colored regions show areas where more positively charged 
groups are favourable, and red regions highlight areas where groups with more negative partial charges 
are favourable. 
The CoMFA steric contours of the most active molecule CHK2759M41 is displayed in Figure 7. 
A large green region (G1) near the 6-position of CHK2759M41 indicates that a bulky substituent is 

































































preferred in the position to produce higher inhibitory activity. This is in agreement with the fact that the 
inhibitory activities of compounds CHK2759M38 and CHK2759M42 with more bulky substituents 
( with aliphatic hydrocarbon )in G1 are higher than compound CHK3618M5（-H）. Also, compounds 
CHK2759M39 and CHK2759M41, which are cyclohexane analogues, showed higher activity than 
compound CHK3618M5（-H）.And that cyclohexane ring interacts with the hydrophobic surface of the 
side chains of Tyr86, Ser88, Thr14, Asp94 and Glu17. So this volume (G1) is in agreement with the 
receptor structure. 
Two yellow contours (Y1, Y2) were observed which suggest that compounds with substituents 
entering these contours are less active than those with substituents that do not entering these contours. 
Figure 3 shows that residues Phe149, Glu55, Lys38 and Leu84 in the binding pocket of the CHK1 are 
in the distance of less than 3.0 Å to Y1 and Y2 of these inhibitors. Therefore, any larger substitutes 
may lead to steric collision with those residues in the pocket. One finding lend further support to this 
opinion, the activity of compound CHK2759M41 decreases quickly after the -OH groups are replaced 
by bulky groups, just like CHK2759M31 which has benzene ring group in Y1 and Y2 . 
Due to the steric collision with these residues in Y1 and Y2, those compounds move downward 
and the hydroxybenzenes of those compounds entering into the large green contour map(G3).This large 
region of green contour (G3) around the 3-position of the CHK2759M41 suggests that steric bulk is  
favourable there. For example, the activity of compounds CHK5944M23 and CHK5944M24 (with 
abenzene ring) are higher than compound CHK5944M22 (with a acetylene).It can be see in Figure 3 
that the benzene ring interacts with the hydrophobic surface of the side chains of Leu84, Ile56, Val56 
and Phe149. So this region (G3) is in agreement with the receptor structure. 
The electrostatic contour map of the CoMFA model is shown in Figure 8. To facilitate the 
visualization, the most potent compound CHK2759M41 is overlaid on the map. 
R1 suggests that electronegative groups at this position are favourable for inhibitory activity. For 
example, the high active compounds CHK2758M22，CHK2758M23，CHK2758M24，CHK2758M25，
CHK2758M26，CHK2758M27 and CHK2758M28 have electronegative groups (carboxy) located in 
this red contour. As indicated in Figure 3, Lys38 which containing positive groups in this region (R1), 
has a strong electrostatic interaction with the negative charged groups (carboxy) of those inhibitors. 
Two red contours (R2, R3) observed next to the plane of the benzene ring are contributed by the 
nitrile group in compounds CHK5944M40 to CHK5944M50 and are taken as an indication of the role 
of electronegative groups at these positions in increasing the inhibitory activity. Nitrile groups have an 
overall negative-charge and hence show reasonable activity. Furthermore, Asn59 containing positive 
groups rather near this region (R2, R3), has a strong electrostatic interaction with the negative charged 
substitute groups of the inhibitors. Also, the hydrogen in the -NH group is electrophilic, further 
docking study showed that the -NH groups of Asn59 or Phe149 might form H-bonds with the -OH 
groups of CHK4308M5-CHK4308M52.  
Two large blue (B1 and B2) regions near Glu55, Gly150 and Asp148 suggest that electropositive 
substituents would increase the inhibitory activity. Those residues have a hydroxyl. The docking result 
of the potent inhibitor CHK2759M41 showed that the hydroxyl groups of CHK4308M5 to 
CHK4308M52 donated a hydrogen bond to Glu55. 
A large blue contour (B3) is noticed in 6-position of CHK2759M41. As show in Figure 9, a small 

































































area of blue (B4) contour around the 7-position of CHK2759M41 indicates that electropositive 
substituents are favourable there. As the experimental data shown, compounds CHK4308M7、
CHK4308M9、CHK4308M26、CHK4308M27 and CHK4308M28 which have a methyl group on that 
position have higher pIC50 values from 0.1 to 1 nM. 
In Figure 10, the blue contour region (B5) shows that electropositive groups are favourable in this 
region. Inhibitors 42 and CHK3618M24 which contain partially positive charged groups (methyl) in 
this region show higher pIC50 values.  
 
3.3 Validation of the 3-D QSAR Models 
The thirty randomly selected compounds (Table 3) were used as the testing set to verify the constructed 
CoMFA model. The calculated results are listed in Table 3 and displayed in Figure 7. The predicted 
pIC50 values were in good agreement with the experimental data within a statistically tolerable error 
range, with a correlation coefficient of r2=0.812 for CoMFA model. The test results indicated that the 
CoMFA model would be reliable for new CHK1 inhibitors designing and developing drug leads 
against cancer. 
4 Conclusions  
In this study, CoMFA models have been built to explain the structure-activity relationship of a series of 
1, 4-dihydroindeno[1,2-c]pyrazoles derivatives. The developed CoMFA model showed a good 
predictive power with low residuals for test set molecules. In addition, the 3D-QSAR results suggested  
that the hydrophobic group is the favourable group in the G3 region of those 
1,4-dihydroindeno[1,2-c]pyrazoles derivatives. Also, the hydrophobic group is the favourable group in 
the G1 region of the 1, 4-dihydroindeno[1,2-c]pyrazoles derivatives. And the docking study revealed 
that a lot of inhibitors establish hydrogen bonds with Glu55 and Phe149, Asn59, Cys87, Glu85, Leu15. 
These results demonstrated the power of a combined docking/QSAR approach to explore the probable 
binding conformations of compounds at the active site of the protein target, and further provided useful 
information in understanding the structural and chemical features of 1,4-dihydroindeno[1,2-c]pyrazoles 
derivatives in designing and finding new potential inhibitors.  
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Figure 2.  Binding conformations of the cocrystallized CHK2759M41 and redocked CHK2759M41 at the active sites of CHK1. 







































































Figure 3.  Position of docked inhibitor CHK2759M41 in the binding pocket of CHK1. H-bonds and interactions between 















































































































































                                          
Figure 5.  Correlation between predicted activities by CoMFA model and the experimental pIC50 values of training set  
 













































































































































Figure 8.  CoMFA electrostatic field distribution contour map in combination with inhibitor CHK2759M41 
 
 
   Figure 9.  CoMFA electrostatic field distribution contour map in combination with inhibitor CHK4308M7 
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Table 1 
Inhibitory activity of 1,4-dihydroindeno[1,2-c]pyrazoles derivatives 
 
   
   
  

































































   














X R IC50(nM) pIC50 




2 CHK2759M8 A trans   F 814 6.09 
3 CHK2759M9 A trans   H 1473 5.83 
4 CHK2759M10 A trans   Cl 481 6.32 
5 CHK2759M11 A trans   NH2 1042 5.98 
6 CHK2759M12 A trans   CH2COMe 497 6.3 
7 CHK2759M13 A trans   CH2OH 790 6.1 












12 CHK2759M18 A trans   COOMe 602 6.22 
13 CHK2759M19 A trans   OH 124 6.91 

































































14 CHK2759M20 A trans   COOH 22 7.66 
15 CHK2759M21 A cis   COOH 20 7.70 










18 CHK2759M24 B   
 
COOH 6.0 8.22 
19 CHK2759M25 B   
 
COOH 15 7.82 
20 CHK2759M26 B   
 
COOH 12 7.92 
21 CHK2759M27 B   
 
COOH 12 7.92 



































29 CHK2759M37 C   
 
 2.0 8.70 
30 CHK2759M38 C   
 
 6.6 8.18 
31 CHK2759M40 C   
 
 7.4 8.13 

































































32 CHK2759M41 C   
 
 6.2 8.21 
33 CHK2759M42 C   
 
 4.0 8.40 
34 CHK2759M43 C   
 
 13 7.89 
35 CHK2759M44 C   
 
 3.6 8.44 
36 CHK3618M5 C   H  1373 5.86 
37 CHK3618M6 C   
 
 24 7.62 
38 CHK3618M7 C   
 
 9.3 8.03 
39 CHK3618M8 C   OH  4.4 8.36 
40 CHK3618M9 C   CH2OH  7.7 8.11 
41 CHK3618M10 C   
 
 6.4 8.19 
42 CHK3618M11 C   
 
 1.2 8.92 
43 CHK3618M12 C   
 
 2.1 8.68 
44 CHK3618M13 C   
 
 0.74 9.13 
45 CHK3618M15 D  5 
CH2OH 
 
 7.8 8.11 
46 CHK3618M16 D  5 
 
 209 6.68 
47 CHK3618M19  D  7 
CH2OH 
 
 4.4 8.36 
48 CHK3618M20 D  7 
 
 34 7.47 

































































49 CHK3618M21 D  7 
 
 12 7.92 
50 CHK3618M22  D  7 
 
 5.2 7.82 
51 CHK3618M23 D  7 
 
 7.1 8.15 
52 CHK3618M24 D  7 
 
 5.0 8.300 
53 CHK3618M25  D  7 
 
 2.3 8.64 
54 CHK3618M33 E   
 
 0.24 9.62 
55 CHK3618M34 E   
 
 2.3 8.64 
56 CHK3618M35 E   
 
 0.83 9.08 
57 CHK3618M36 E   
 
 0.24 9.62 
58 CHK3618M37 E   
 
 0.55 9.26 





 0.43 9.37 
60 CHK3618M39 E   
 
 0.51 9.29 
61 CHK3618M40 E   
 
 0.21 9.68 
62 CHK3618M41 E   
 
 0.56 9.25 
63 5           F    
 
2 8.70 

































































64 6 F    
 
2 8.70 
65 7 F    
 
0.7 9.15 
66 8 F    
 
2 8.70 




68 10 F    
 
1 9.00 
69 11 F    
 
4 8.40 
70 12 F    
 
2 8.70 
71 13 F    
 
6 8.22 
72 14 F    
 
25 7.60 
73 15 F    
 
8 8.10 
74 16 F    
 
8 8.10 
75 17 F    
 
18 7.74 
76 18 F    
 
20 7.70 




78 20 F    
 
13 7.89 

































































79 21 F    
 
30 7.52 
80 22 F    
 
23 7.64 
81 23 F    
 
62 7.21 
82 24 F    
 
5 8.30 
83 26 F    
 
0.1 10.00 
84 27 F    
 
0.1 10.00 
85 28 F    
 
0.8 9.10 
86 29 F    
 
0.2 9.70 
87 30 F    
O  
0.4 9.40 
88 31           F    
 
0.7 9.15 
89 32 F    H 1 9.00 
90 33 G    H 5 8.30 
91 34           G    
 
0.8 9.10 
92 35   G    
 
2 8.70 
93 36 G    
 
0.6 9.22 
94 37 G    
 
2 8.70 
95 38 G    
 
0.8 9.10 
96 39 G    
 
0.2 9.70 
97 40 G    
 
0.6 9.22 

































































98 41 G    
 
5 8.30 
99 42 G    
 
2 8.70 
100 43 G    
 
10 8.00 
101 44 G    
 
3 8.52 
102 45 G    
 
24 7.62 
103 46 G    
 
23 7.64 
104 47 G    
 
36 7.44 
105 48 G    
 
40 7.40 
106 49 G    
 
21 7.68 
107 50 G    
 
74 7.13 
108 51 G    
 
48 7.32 
109 CHK5944M2 H    
 
2 8.70 
110 CHK5944M3 H    OH 25 7.60 
111 CHK5944M4 H    CN 7 8.15 
112 CHK5944M5 H    COOH 2 8.70 
113 CHK5944M6 H    
 
25 7.60 
114 CHK5944M7 H    
 
779 6.11 

































































115 CHK5944M8 H    
 
355 6.45 
116 CHK5944M10 H    Br 73 7.14 
117 CHK5944M13 H    
 
6223 5.21 
118 CHK5944M15 H    
 
11 7.96 
119 CHK5944M16 H    
 
47 7.33 
120 CHK5944M17 H    
 
77 7.11 
121 CHK5944M18 H    
 
1260 5.90 
122 CHK5944M19 H    
 
1374 5.86 
123 CHK5944M20 H    
 
3709 5.43 
124 CHK5944M21 H    
 
3003 5.52 
125 CHK5944M22 I    H 5140 5.29 









128 CHK5944M29 J    
 
0.8 9.10 
129 CHK5944M30 J    
 
15 7.82 
130 CHK5944M31 J    
 
4 8.40 

































































131 CHK5944M32  J    
 
2 8.70 
132 CHK5944M35 J    
 
16 7.80 
133 CHK5944M37 J    
 
44 7.36 
134 CHK5944M38  J    
 
89 7.05 
135 CHK5944M39 J    
 
44 7.36 
136 CHK5944M40 K    
 
4 8.40 
137 CHK5944M41 K    
 
3 8.52 
138 CHK5944M42 K    
 
3 8.52 
139 CHK5944M43 K    
 
6 8.22 
140 CHK5944M44 K    
 
14 7.85 
141 CHK5944M45 K    
 
20 7.70 
142 CHK5944M46 K    
 
10 8.00 
143 CHK5944M47 K    
 
77 7.11 
144 CHK5944M48 K    
 
9 8.05 
145 CHK5944M49 K    
 
2 8.70 

































































146 CHK5944M50  K    
 
3 8.52 
147 CHK5944M51 K    
 
2 8.70 
148 CHK5944M52 K    
 
1 9.00 
149 CHK5944M53 K    
 
3 8.52 
150 CHK5944M54 K    
 
17 7.77 







Actual and predicted inhibitory activities (pIC50) and residuals of the training set molecules 
 
NO Compound numbers ChemScore 
 
pIC50 Predicted Residuals 
1 10 43.39 9.000 8.822 0.178 
2 11 43.56 8.398 8.961 -0.563 
3 12       45.02 8.699 8.781 -0.082 
4 13 45.24 8.222 8.323 -0.101 
5 14 42.53 7.602 7.353 0.249 
6 15 45.04 8.097 8.314 -0.217 
7 16 45.82 8.097 8.098 -0.001 
8 18 44.73 7.699 7.969 -0.270 
9 19 43.50 8.301 8.425 -0.124 
10 20 43.83 7.886 8.214 -0.328 
11 21 43.31 7.523 7.385 0.138 
12 22 44.77 7.638 7.691 -0.053 
13 23 44.26 7.208 7.831 -0.623 
14 24 43.63 8.301 8.154 0.147 
15 27 43.21 10.000 9.689 0.311 
16 28 45.98 9.097 9.006 0.091 
17 29 42.83 9.699 9.316 0.383 
18 31 44.35 9.155 8.839 0.316 
19 32 45.62 9.000 9.034 -0.034 

































































20 33 45.48 8.301 8.765 -0.464 
21 36 42.49 9.222 9.066 0.156 
22 37 44.29 8.699 8.778 -0.079 
23 39 43.96 9.699 9.421 0.278 
24 40 41.33 9.222 9.391 -0.169 
25 42 39.12 8.699 8.522 0.177 
26 44 42.31 8.522 8.773 -0.251 
27 46 44.00 7.638 7.271 0.367 
28 47 44.18 7.444 7.288 0.156 
29 48 44.80 7.398 7.112 0.286 
30 49 43.99 7.678 7.911 -0.233 
31 5 43.12 8.699 8.781 -0.082 
32 50 44.29 7.131 7.673 -0.542 
33 7 43.86 9.155 8.893 0.262 
34 8 46.22 8.699 8.717 -0.018 
35 9 43.40 9.099 8.398 0.701 
36 CHK2759M11 37.51 5.982 5.739 0.243 
37 CHK2759M13 39.45 6.102 6.124 -0.022 
38 CHK2759M14 38.91 6.015 5.662 0.353 
39 CHK2759M15 40.31 5.796 6.002 -0.206 
40 CHK2759M17 40.52 5.279 5.321 -0.042 
41 CHK2759M18 40.42 6.220 6.127 0.093 
42 CHK2759M19 35.72 6.907 6.491 0.416 
43 CHK2759M20 37.69 7.658 7.601 0.057 
44 CHK2759M21 39.25 7.699 7.454 0.245 
45 CHK2759M22 35.38 7.823 7.91 -0.087 
46 CHK2759M23 36.94 8.102 7.737 0.365 
47 CHK2759M24 37.05 8.222 7.96 0.262 
48 CHK2759M26 38.37 7.921 8.524 -0.603 
49 CHK2759M28 36.08 7.161 7.541 -0.380 
50 CHK2759M29 35.60 7.538 7.501 0.037 
51 CHK2759M30 38.20 6.272 6.254 0.018 
52 CHK2759M31 40.43 5.058 5.137 -0.079 
53 CHK2759M32 40.03 5.317 5.384 -0.067 
54 CHK2759M35 41.73 5.726 5.802 -0.076 
55 CHK2759M36 39.07 5.189 4.842 0.347 
56 CHK2759M37 41.12 8.699 8.531 0.168 
57 CHK2759M40 47.68 8.131 8.081 0.050 
58 CHK2759M41 48.52 8.208 8.099 0.109 
59 CHK2759M42 44.21 8.398 8.548 -0.150 
60 CHK2759M43 44.35 7.886 7.634 0.252 
61 CHK2759M44 40.62 8.444 8.421 0.023 
62 CHK2759M7 38.46 6.338 6.925 -0.587 
63 CHK2759M8 37.26 6.089 6.192 -0.103 

































































64 CHK2759M9 37.74 5.832 5.977 -0.145 
65 CHK3618M11 46.11 8.921 8.981 -0.060 
66 CHK3618M12 45.50 8.678 8.711 -0.033 
67 CHK3618M13 46.36 9.131 9.167 -0.036 
68 CHK3618M16 46.18 6.680 7.246 -0.566 
69 CHK3618M19 44.35 8.357 8.412 -0.055 
70 CHK3618M21 41.66 7.921 7.436 0.485 
71 CHK3618M22 43.65 7.824 7.633 0.191 
72 CHK3618M24 39.99 8.301 8.615 -0.314 
73 CHK3618M25 41.79 8.638 8.593 0.045 
74 CHK3618M33 43.40 9.619 9.066 0.553 
75 CHK3618M34 42.42 8.638 8.702 -0.064 
76 CHK3618M35 44.99 9.081 8.908 0.173 
77 CHK3618M37 43.87 9.259 9.063 0.196 
78 CHK3618M38 45.76 9.367 8.817 0.550 
79 CHK3618M39 40.95 9.292 9.599 -0.307 
80 CHK3618M40 46.44 9.678 9.022 0.656 
81 CHK3618M41 47.03 9.252 9.141 0.111 
82 CHK3618M5 43.65 5.862 6.021 -0.159 
83 CHK3618M6 42.84 7.620 7.936 -0.316 
84 CHK3618M7 44.76 8.032 8.165 -0.133 
85 CHK3618M9 44.00 8.113 7.905 0.208 
86 CHK5944M10 36.01 7.137 6.899 0.238 
87 CHK5944M13 39.24 5.206 5.190 0.016 
88 CHK5944M15 40.73 7.959 8.139 -0.180 
89 CHK5944M16 42.84 7.328 7.233 0.095 
90 CHK5944M17 40.42 7.114 6.802 0.312 
91 CHK5944M19 37.50 5.862 6.385 -0.523 
92 CHK5944M2 43.02 8.699 8.902 -0.203 
93 CHK5944M20 38.68 5.431 5.164 0.267 
94 CHK5944M21 39.59 5.522 5.651 -0.129 
95 CHK5944M22 38.12 5.289 5.579 -0.290 
96 CHK5944M24 34.22 8.301 8.125 0.176 
97 CHK5944M28 40.54 9.301 9.472 -0.171 
98 CHK5944M30 32.86 7.824 7.752 0.072 
99 CHK5944M31 34.64 8.398 8.003 0.395 
100 CHK5944M32 32.69 8.699 8.351 0.348 
101 CHK5944M35 35.13 7.796 7.870 -0.074 
102 CHK5944M37 32.86 7.357 7.629 -0.272 
103 CHK5944M38 32.11 7.051 7.285 -0.234 
104 CHK5944M39 29.26 7.357 7.315 0.042 
105 CHK5944M4 34.32 8.155 7.742 0.413 
106 CHK5944M40 34.03 8.398 8.615 -0.217 
107 CHK5944M42 36.51 8.523 8.816 -0.293 

































































108 CHK5944M43 38.50 8.222 8.383 -0.161 
109 CHK5944M44 36.64 7.854 7.367 0.487 
110 CHK5944M45 35.62 7.699 7.773 -0.074 
111 CHK5944M47 36.19 7.114 7.302 -0.188 
112 CHK5944M48 36.37 8.046 8.445 -0.399 
113 CHK5944M49 35.47 8.699 8.705 -0.006 
114 CHK5944M5 34.87 8.699 8.571 0.128 
115 CHK5944M51 34.65 8.699 8.417 0.282 
116 CHK5944M53 35.03 8.523 8.421 0.102 
117 CHK5944M54 36.83 7.770 7.947 -0.177 
118 CHK5944M55 36.39 8.699 8.624 0.075 
119 CHK5944M6 37.32 7.602 7.279 0.323 
120 CHK5944M7 35.30 6.108 6.811 -0.703 













pIC50 Predicted Residuals 
1 17 46.45 7.745 8.265 -0.52 
2 26 45.89 10.000 9.239 0.761 
3 30 44.59 9.398 8.818 0.58 
4 34 43.10 9.097 8.519 0.578 
5 35 42.07 8.699 8.505 0.194 
6 38 41.92 9.097 8.676 0.421 
7 41 42.01 8.301 8.585 -0.284 
8 43 45.35 8.000 8.387 -0.387 
9 45 43.44 7.620 8.096 -0.476 
10 51 45.01 7.319 7.569 -0.25 
11 6 42.63 8.699 8.135 0.564 
12 CHK2759M10 39.28 6.318 6.311 0.007 
13 CHK2759M12 42.81 6.304 6.897 -0.593 
14 CHK2759M16 36.23 5.690 6.265 -0.575 
15 CHK2759M25 38.37 7.824 8.122 -0.298 
16 CHK2759M27 39.12 7.921 7.697 0.224 
17 CHK2759M38 45.28 8.180 8.542 -0.362 
18 CHK3618M10 47.64 8.194 8.554 -0.36 
19 CHK3618M15 44.39 8.108 8.225 -0.117 
20 CHK3618M20 42.75 7.469 8.187 -0.718 

































































21 CHK3618M23 42.42 8.149 8.348 -0.199 
22 CHK3618M36 43.40 9.620 8.965 0.655 
23 CHK3618M8 44.67 8.357 8.199 0.158 
24 CHK5944M18 41.29 5.900 6.813 -0.913 
25 CHK5944M29 32.61 9.097 8.496 0.601 
26 CHK5944M3 33.18 7.602 7.637 -0.035 
27 CHK5944M41 36.79 8.523 8.225 0.298 
28 CHK5944M46 35.77 8.000 8.089 -0.089 
29 CHK5944M50 36.97 8.523 7.794 0.729 







Table 4. Summary of CoMFA analysis. 
 
Parameters CoMFA 
Training set - 
PLS statistics - 
LOO - 
q2 (CV correlation coefficient) 0.534 
N (number of components) 6 
Uncross-validated - 
r2 (correlation coefficient) 0.911 
SEE (standard error of estimate) 0.352 
F (F-ratio) 187.106 
Field distribution - 
Steric 43.0% 
Electrostatic 57.0% 
Testing set - 
r2 (correlation coefficient) 0.812 
S (standard error of prediction) 0.313 
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